We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Orphan

News List

Adial Pharma Selects Crown CRO for Phase III Trial contractpharma
November 28, 2018
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has selected Crown CRO, based in Finland, to manage its Phase III trial for AD04 for the treatment of alcohol use disorder (AUD).
Selumetinib Granted Orphan Designation in Europe americanpharmaceuticalreview
August 06, 2018
AstraZeneca and Merck announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Abeona Therapeutics receives FDA orphan designation for gene therapy europeanpharmaceuticalreview
May 31, 2017
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Abeona Therapeutics’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB).
Spark Therapeutics Earns $15M Pfizer Milestone contractpharma
January 06, 2017
Spark Therapeutics has earned a $15 million milestone payment from Pfizer for achieving a pre-specified safety and efficacy profile in the ongoing hemophilia B Phase 1/2 trial of SPK-9001.

Previous page 1 2 3 Next page